SB 2485 Summary

• Authorizes licensed physicians to prescribe or recommend investigational drugs, biological products, or devices to terminally ill patients who have exhausted FDA-approved treatment options and provided written informed consent.

• Defines eligible patients as those with terminal illnesses who have considered all approved treatments and clinical trials, received physician recommendation, and provided comprehensive written informed consent (or parent/guardian consent if minor).

• Defines investigational products as drugs or devices that completed Phase 1 clinical trials but lack FDA approval, excluding Schedule I controlled substances.

• Prohibits state regulatory boards from revoking or denying license renewal to physicians or pharmacists based solely on recommending investigational treatments to eligible patients under this act.

• Provides civil liability immunity to manufacturers, physicians, pharmacists, and others involved in providing investigational treatments, except in cases of gross negligence or willful misconduct; does not require health insurers, hospitals, or the Department of Corrections to cover costs.